Harmony Biosciences Holdings, I (HRMY) concentration risks

The company's concentration profile is dominated by three interlocking high-share exposures that collectively define the risk architecture. On the revenue side, substantially all revenue is expected to derive from WAKIX for the foreseeable future — a mixed-character concentration that is structural (reflecting a single approved product stage of the company) but also carries dependency traits since any disruption to that product's commercial trajectory has no offsetting revenue stream. The character is mixed because while single-product reliance is typical of companies at this stage, it does leave the financial profile with no diversification cushion. Layered directly beneath that are two high-share supply-side exposures. The company relies completely on third parties — including certain sole-source suppliers and manufacturers — to produce and distribute WAKIX and its pipeline candidates. Separately, the core intellectual property underpinning pitolisant, the active ingredient in WAKIX, is licensed from Bioprojet, creating a high-share counterparty dependency at the IP level. These three exposures stack rather than offset: a single product drives all revenue, that product is manufactured by a supply chain with sole-source nodes, and the underlying IP sits in a third-party license. Any disruption at any layer — commercial, manufacturing, or licensing — propagates directly to the top line with no buffer. This is the dominant feature of the disclosed concentration profile and is a primary variable an investor should monitor.

For the engine’s reasoning on HRMY’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.